Artiva Biotherapeutics, Inc.
ARTV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $251 | $33,492 | $4,931 | $2,002 |
| % Growth | -99.3% | 579.2% | 146.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $251 | $33,492 | $4,931 | $2,002 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $50,328 | $50,251 | $43,984 | $42,410 |
| G&A Expenses | $17,205 | $13,912 | $20,776 | $12,864 |
| SG&A Expenses | $17,205 | $13,912 | $20,776 | $12,864 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $67,533 | $64,163 | $64,760 | $55,274 |
| Operating Income | -$67,282 | -$30,671 | -$59,829 | -$53,272 |
| % Margin | -26,805.6% | -91.6% | -1,213.3% | -2,660.9% |
| Other Income/Exp. Net | $8,789 | $3,047 | $1,494 | -$18,553 |
| Pre-Tax Income | -$58,493 | -$27,624 | -$58,335 | -$71,825 |
| Tax Expense | $0 | $72 | $53 | $0 |
| Net Income | -$58,493 | -$27,696 | -$58,388 | -$71,825 |
| % Margin | -23,304% | -82.7% | -1,184.1% | -3,587.7% |
| EPS | -5.2 | -1.19 | -3.32 | -4.08 |
| % Growth | -337% | 64.2% | 18.6% | – |
| EPS Diluted | -5.2 | -1.19 | -3.32 | -4.08 |
| Weighted Avg Shares Out | 24,363 | 23,282 | 17,583 | 17,583 |
| Weighted Avg Shares Out Dil | 24,363 | 23,282 | 17,583 | 17,583 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,349 | $2,535 | $1,294 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,431 | $2,266 | $1,158 | $248 |
| EBITDA | -$64,851 | -$28,405 | -$58,671 | -$71,577 |
| % Margin | -25,837.1% | -84.8% | -1,189.8% | -3,575.3% |